Experimental PrEP drug injected once every two months to begin global trial...


avert.org | 2017-06-15 13:52 UTC

Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.

By AVERT on 2017-06-15 13:52 UTC
  • Need an account?  
    or